Welcome to our dedicated page for Bridgebio Pharma SEC filings (Ticker: BBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BridgeBio Pharma, Inc. (NASDAQ: BBIO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. BridgeBio is a biopharmaceutical company focused on medicines for genetic diseases, and its filings give detailed insight into clinical milestones, financial condition, capital structure, and corporate governance.
Current reports on Form 8-K are a key source of information for BBIO. The company uses 8-K filings to report material events such as positive Phase 3 topline results for encaleret in autosomal dominant hypocalcemia type 1 and for BBP-418 in LGMD2I/R9, quarterly business updates and financial results, and significant agreements like royalty interest purchase and sale arrangements tied to acoramidis royalties in Europe. 8-Ks also describe shareholder votes on amendments to the certificate of incorporation, stock incentive plans, and other governance matters.
Investors can also review filings that discuss BridgeBio’s financing activities, including proposed offerings of convertible senior notes and the terms, ranking, and convertibility features of such instruments, as well as transactions that monetize future royalty streams. These documents help explain how the company funds commercialization of Attruby (acoramidis) and its broader development pipeline.
On Stock Titan, BBIO filings are updated as new documents are posted to EDGAR. AI-powered summaries highlight the main points of long forms such as 8-Ks, so readers can quickly see why a filing was made, what agreements or results were disclosed, and how it may relate to BridgeBio’s clinical programs, ATTR-CM franchise, or capital structure. Users can drill down into individual filings for full legal and financial detail, including exhibits referenced in the company’s reports.
BridgeBio Pharma filed a Form 144 reporting a proposed sale of 50,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $2,400,000. The filing shows 191,168,504 shares outstanding.
The 50,000 shares to be sold were acquired on 07/01/2019 as founders' shares from the issuer and paid for in cash. The filing also discloses three sales by Charles J Homcy on 08/08/2025 totaling 250,000 common shares with gross proceeds of $6,907,905, $2,302,295 and $2,302,220 (combined $11,512,420).
BridgeBio Pharma, Inc. (BBIO) filed a Form 144 disclosing a proposed sale of 250,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $11,512,420.00 and total shares outstanding reported as 191,168,504. The securities were acquired as founder shares on 07/01/2019 from the issuer and payment was recorded on that date. The filing reports no securities sold during the past three months. The notice includes the required representation about no undisclosed material adverse information. The document does not provide identifying filer contact details or a listed plan adoption date for any Rule 10b5-1 trading plan.
Form 144 summary for BridgeBio Pharma, Inc. (BBIO)
This Form 144 reports an insider sale on 08/05/2025: 17,167 common shares sold through Morgan Stanley Smith Barney LLC (Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004) with an aggregate market value of $841,183.00. The filing lists 189,880,720 shares outstanding. The securities were acquired and paid for on 08/05/2025 via a stock option exercise from the issuer with cash payment. The filer reports "Nothing to Report" for securities sold in the past three months.
Note: Several filer and issuer contact fields in the form are blank in the provided text.
FAQ
What is the current stock price of Bridgebio Pharma (BBIO)?
What is the market cap of Bridgebio Pharma (BBIO)?
